NCT03252938 2026-02-19
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Active not recruiting
Clinical Trials
14 trialsNCT04220827 2025-10-27
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03740165 2025-10-22
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03732768 2025-08-22
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Oncoinvent Solutions AS
Phase 1 Active not recruiting
NCT05617755 2025-07-30
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
Phase 1 Active not recruiting
NCT03348150 2025-07-17
PERISCOPEII
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT05257408 2025-04-16
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
Phase 3 Active not recruiting
NCT05623787 2025-03-20
DWI-HighRisk
Laval University
Phase NA Active not recruiting
NCT05185947 2025-03-07
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02758951 2024-11-25
CAIRO6
Catharina Ziekenhuis Eindhoven
Phase 2/3 Active not recruiting
NCT03172416 2024-05-29
PIPAC
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT04000906 2024-05-24
Nab-PIPAC
University Hospital, Geneva
Phase 1 Active not recruiting
NCT02113384 2021-07-28
LARC-EX
Oslo University Hospital
Active not recruiting